Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 35.89% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTLongeveron Inc.'s latest supported as-filed period reports revenue of $287,000; gross margin moved 1721 basis points higher on the same comparison basis. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 35.89% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -1969.69% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -9.18% · CORE
Level · gp.fundamentals.gross_margin
Raw value 63.41% · CORE
Level · gp.fundamentals.operating_margin
Raw value -2150.17% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 1112.89% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -2.5% from the comparable as-filed period.
Gross margin changed +1721 basis points from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Gross profit changed +24.7% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
LGVN · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001214659-26-010852SEC ↗8-KAug 24, 2026Period Aug 20, 20260001213900-26-093028SEC ↗4Aug 21, 2026Period Aug 19, 20260001214659-26-010743SEC ↗4Aug 21, 2026Period Aug 19, 20260001214659-26-010742SEC ↗4Aug 21, 2026Period Aug 19, 20260001214659-26-010741SEC ↗4Aug 21, 2026Period Aug 19, 20260001214659-26-010740SEC ↗4Aug 21, 2026Period Aug 19, 20260001214659-26-010739SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 17, 2026Filed Aug 25, 2026 | Jhaveri Nirav S.Chief Financial Officer | Grant Or AwardDirect | 300,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.sbc_revenue_ratio
Raw value 129.97% · OPTIONAL
Net income changed -20.8% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Operating income changed -14.3% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Operating margin changed -44226 basis points from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Research & development changed +8.1% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001214659-26-010736